Skip to main content
Log in

Significant reversal of thyrotoxicosis-associated dilated cardiomyopathy with induction of the euthyroid state

  • Case Report
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Thyrotoxicosis rarely precipitates heart failure. Older patients and those with underlying cardiac disease are at greater risk of experiencing this complication of thyrotoxicosis. A 43 year old male who presented with subclinical thyrotoxicosis, atrial fibrillation, and a dilated cardiomyopathy is discussed. There was no evidence of clinically significant underlying cardiac disease. At admission, the patient had an ejection fraction of 25%. Thyrotoxicosis was treated with propylthiouracil. At 14 weeks after hospitalization, the patient had an ejection fraction of 50% with significant reduction in cardiac chamber sizes and left ventricular mass index. He was biochemically euthyroid at that time. After ten months of propylthiouracil therapy, he had progressive improvement in cardiac function and decrease in left ventricular mass index. Thyrotoxicosis-associated cardiomyopathy may reverse significantly with treatment of thyrotoxicosis alone; this complication of thyrotoxicosis should be considered in any young individual with a dilated cardiomyopathy of unknown etiology.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Amidi M., Leon D.F., deGroot J., Kroetz F.W., Leonard J.J. Effect of the thyroid state on the myocardial contractility and ventricular ejection rate in man. Circulation 38: 229, 1968.

    Article  CAS  PubMed  Google Scholar 

  2. Sandler G., Wilson G.M. The nature and prognosis of heart disease in thyrotoxicosis: a review of 150 patients treated with 131I. Q. J. Med. 28: 347, 1959.

    CAS  PubMed  Google Scholar 

  3. Symons C., Richardson P.J., Feizi O. Hypertrophic cardiomyopathy and hyperthyroidism: a report of three cases. Thora 29: 713, 1974.

    Article  CAS  Google Scholar 

  4. Forfar J.C., Muir A.L., Sawers S.A., Toft A.D. Abnormal left ventricular function in hyperthyroidism: evidence for a possible reversible cardiomyopathy. N. Engl. J. Med. 307: 1165, 1982.

    Article  CAS  PubMed  Google Scholar 

  5. Magner J.A., Clark W., Allenby P. Congestive heart failure and sudden death in a young woman with thyrotoxicosis. West. J. Med. 149: 86, 1988.

    CAS  PubMed Central  PubMed  Google Scholar 

  6. Ikram H. The nature and prognosis of thyrotoxic heart disease. Q. J. Med. 54: 19, 1985.

    CAS  PubMed  Google Scholar 

  7. Izumo S., Nadal-Ginard B., Mahdavi V. All members of the MHC multigene family respond to thyroid hormone in a highly tissue-specific fashion. Science 231: 597, 1986.

    Article  CAS  PubMed  Google Scholar 

  8. Dillmann W.H. The cardiovascular system in thyrotoxicosis. In: Braverman L.E., Utiger R.D., (Eds.), Werner and Ingbar’s The Thyroid, ed. 6. Lippincott, Philadelphia, 1991, p. 759.

    Google Scholar 

  9. Cavallo A., Joseph C., Casta A. Cardiac complications in juvenile hyperthyroidism. Am. J. Dis. Child. 138: 479, 1984.

    CAS  PubMed  Google Scholar 

  10. Wilson B.E., Newmark S.R. Thyrotoxicosis-induced congestive heart failure in an urban hospital. Am. J. Med. Sci. 308: 344, 1994.

    Article  CAS  PubMed  Google Scholar 

  11. Biondi B., Fazio S., Carella C., Amato G., Cittadini A., Lupoli G., Saccè L., Bellastella A., Lombardi G. Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine. J. Clin. Endocrinol. Metab. 77: 334, 1993.

    CAS  PubMed  Google Scholar 

  12. Biondi B., Fazio S., Carella C., Sabatini D., Amato G., Cittadini A., Bellastella A., Lombardi G., Saccè L. Control of adrenergic overactivity by ß-blockade improves the quality of life in patients receiving long-term suppressive therapy with levothyroxine. J. Clin. Endocrinol. Metab. 78: 1028, 1994.

    CAS  PubMed  Google Scholar 

  13. Ladenson P.W., Sherman S.I., Baughman K.I., Ray P.E., Feldman A.M. Reversible alterations in myocardial gene expression in a young man with dilated cardiomyopathy and hypothyroidism. Proc. Natl. Acad. Sci. (USA) 89: 5251, 1992.

    Article  CAS  Google Scholar 

  14. Wilson B.E., Hobbs W.N. Pseudoephedrine-associated thyroid storm: thyroid hormone-catecholamine interactions. Am. J. Med. Sci. 306: 317, 1993.

    Article  CAS  PubMed  Google Scholar 

  15. Woeber K.A. Thyrotoxicosis and the heart. N. Engl. J. Med. 327: 94, 1992.

    Article  CAS  PubMed  Google Scholar 

  16. Liggett S.B., Shah S.D., Cryer P.E. Increased fat and skeletal muscle beta-adrenergic receptors but unaltered metabolic and hemodynamic sensitivity to epinephrine in vivo in experimental human thyrotoxicosis. J. Clin. Invest. 83: 803, 1989.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. MacMahon S.W., Wilcken D.E.L., MacDonald G.J. The effect of weight reduction on left ventricular mass. N. Engl. J. Med. 314: 334, 1986.

    Article  CAS  PubMed  Google Scholar 

  18. Wynne J., Braunwald E. The cardiomyopathies and myocarditides: toxic, chemical and physical damage to the heart. In: Braunwald E. (Ed.), Heart disease: A textbook of cardiovascular medicine. W.B. Saunders, Philadelphia. 1992, p. 1394.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wilson, B.E., Hamilton, E.C. Significant reversal of thyrotoxicosis-associated dilated cardiomyopathy with induction of the euthyroid state. J Endocrinol Invest 19, 54–58 (1996). https://doi.org/10.1007/BF03347859

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03347859

Key-words

Navigation